Q-omics provides the consensus-scored CTAGE8 profile across patient tissues and cancer cell-line models. CTAGE8 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CTAGE8 is differentially expressed in 6, with the highest sampling consensus in BLCA. Additionally, CTAGE8 RNA expression shows 12,724 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, BLCA, and UVM as cancer lineages where CTAGE8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTAGE8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTAGE8 survival associations across molecular data types. CTAGE8 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTAGE8 RNA expression–survival associations across cancer types. High CTAGE8 expression shows unfavorable associations in LAML, CHOL, LGG and UCEC, but favorable associations in MESO and SARC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for CTAGE8 RNA expression.
This table summarizes CTAGE8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for CTAGE8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTAGE8 shows lower tumor expression in COAD, THCA and KICH and higher tumor expression in BLCA, LIHC and CHOL. The BLCA box plot shows higher CTAGE8 RNA expression in tumor versus normal tissue (log2 FC = +0.249, t-test p = .007).
This table shows molecular features associated with CTAGE8 in patient tissues and cancer cell lines. In patient samples, CTAGE8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CTAGE8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_NSCLC_LUAD.
